Sodium-glucose cotransporter 2 (SGLT2) inhibitors approved for the treatment of diabetes mellitus have also been reported to lower serum uric acid levels in patients with type 2 DM7,8. This evidence concerns the gene SLC5A2 and diabetes mellitus.